Both vascular and neuronal mechanisms are the main foci of investigation in defining the pathophysiology of migraine attacks. This study was designed to evaluate the possible role of nitric oxide (NO) in migraine patients in the natural course of unprovoked attacks and attack-free periods. The mean plasma nitrite levels of 26 migraine patients during attacks and attack-free periods were compared within group and with those of 26 healthy controls. Plasma total nitrite levels were measured by Greiss reaction. Mean plasma total nitrite levels of migraine patients during attacks and attack-free periods and of controls were 36.5±7.5 μmol/l, 27.81±4.8 μmol/l and 25.19±4.1 μmol/l, respectively. These results demonstrated that total nitrite levels during attacks were significantly higher in migraineurs than both during attack-free periods and those of controls (P=0.001 and P=0.001, respectively). No significant difference was observed between migraineurs during attack-free periods and controls in this regard (P=0.534). Based on these results, we suggest that NO pathway may play a key role in the pathogenesis of migraine attacks.
Introduction
Both vascular and neuronal mechanisms are the main foci of investigation in defining the pathophysiology of migraine attacks. Previous studies revealed that nitric oxide (NO) might have an important role in the pathogenesis of migraine. A number of studies have agreed that NO donors might precipitate migraine attacks and inhibitors might block this effect in migraineurs (1) (2) (3) .
NO is an endogenous molecule released primarily from endothelial cells. NO, which is a potent antiaggregant and causes relaxation of smooth muscle, has an important role in the control of vascular tonus and regulation of systemic blood pressure. It is also involved in pain modulation, since NO synthase (NOS) inhibition causes analgesia in headache via various ways (4, 5) . Existing data in means of NO involvement in migraine have been mostly obtained from studies that were conducted in NO induced headache attacks in healthy subjects and in primary headache cases. However, findings in provoked attacks may not tell us the full story about the role of NO pathways in the natural course of migraine.
We measured the plasma nitrite levels in migraine cases with and without attacks to determine whether they differed from controls in terms of plasma nitrite levels, in attacks or attack-free periods.
Materials and Methods
A total of 26 migraine patients with or without aura were enrolled into the study group; control group consisted of 26 healthy subjects. Migraine was diagnosed using the International Headache Society (IHS) criteria (6) . Twenty-nine patients were asked to participate in the study, 3 of them did not give The eligibility criteria for the migraine patients were diagnosis of migraine (according to IHS criteria), being between 18-50 years of age, accepting to provide a written informed consent and absence of any of the exclusion criteria. The exclusion criteria included presence of hypertension, renal dysfunction, any endocrinological and rheumatologic disease, symptoms of an acute systemic infection, presence of chronic migraine or drug overuse headache, and pregnancy for female subjects.
In healthy volunteers between the ages of 18-50 years who agreed to take part in the study, only the absence of exclusion criteria was checked. A detailed medical history (including symptoms, age, medical history, family history, characteristics of the headache, treatment regimen, symptoms accompanying the headache etc.) was obtained from all migraine and control subjects. Blood pressure was measured and physical and neurological examinations were performed. The sociodemographic and medical information of both patients and control subjects were recorded on a preformed form.
Two samples were obtained from each migraine patient: one during an attack (while the headache is present but prior to use of any medication) and one during attack-free period (without any symptoms for at least 48 hours). Only one sample was taken from control subjects. Ten ml of blood sample was taken from the cubital vein into a tube containing aprotinin (0.6 TIU/ml). The tubes were shaken gently and allowed to stand for 15 minutes, then centrifuged at 1600 g for 10 minutes. The plasma samples were stored at -20°C until the biochemical laboratory evaluation.
Total nitrite reacts with molecular oxygen and accumulates in plasma in the form of nitrite and nitrate ions. Total nitrite, the stable oxidation product of nitrite (NO2) and nitrate (NO3), can be readily measured in biological fluids and used as the indicators of NO products both in vivo and in vitro (7) . Total nitrite was assayed by Greiss reaction after incubation of the supernatant with E. coli nitrate reductase that converts NO3 to NO2. Greiss reagent (1% sulfanilamide and 1% naphthyl ethylenediamide dehydrochloride in 2.5% H3PO4) was added to 1 ml of supernatant and the absorbance was recorded at 545 nm after incubation for 30 minutes (Shimadzu UV mini-1240 Kyoto, Japan). The absorbances were analyzed using the standard curve constructed using NaNO2 which is a reduction product of NaNO3. The reaction was linear between 0.25-100 μmol/l (8).
The assays were confirmed in two ways. The interand intra-assay variations were 7.52% and 4.61%, respectively. In order to control conversion of nitrate to nitrite, a certain amount of nitrate was added to control plasma samples and they were deproteinized as described above. The recovery of nitrate was found to be 98.3±7.09%.
The procedure was the same in both migraine and control cases and the laboratory team that made the assessment was blinded to the groups.
The socio-demographic and clinical characteristics of the patients and controls were presented in simple distribution. 
Results
The migraine group consisted of 22 female (84.6%) and 4 male (15.6%) patients and the control group consisted of 17 female (65.4%) and 9 male (34.6%) subjects. The mean age was 28.65±5.87 (19-47) years and 28.12±5.89 (18-48) years in the migraine group and the control group, respectively. Both groups were similar regarding age and gender (P=0.472 and P=0.349, respectively).
In the migraine group, 11 cases had migraine with aura (42.3%) and 15 had migraine without aura (57.7%). When the incidence of the attacks within the last 3 months was questioned, the data was as follows: 7 patients had 3 to 4 attacks per month (26.9%), 14 had 1 to 2 attacks per month (55.8%) and 5 had 2 to 3 attacks per 1 or 2 months (19.2%). The most commonly experienced accompanying symptom during attacks was photophobia (84.6%). Other common symptoms were nausea (61.5%) and vomiting (61.5%). Mean plasma nitrite levels of migraine patients did not show any significant difference by any demographic variables or associated clinical features (P>0.05, for all parameters). Mean plasma NO levels were significantly higher in migraineurs during attacks (36.5±7.5 μmol/l) compared to both attack-free periods (27.81±4.8 μmol/l) and healthy controls (25.19±4.1 μmol/l) (P=0.001 and P=0.001, respectively) ( Table 1) . Plasma nitrite levels during attack-free periods in migraineurs were found to be similar to the plasma nitrite levels of the controls (P>0.05). There were no statistically significant differences between patients with migraine with and without aura based on plasma nitrite levels either in attack or attack free periods (P>0.05, P>0.05 respectively) ( Table 2 ). 
Discussion
Migraine is a common, chronic and disabling neurovascular disorder. Although the pathogenesis of migraine is still unclear, different vascular, neurological, and neuroinflammatory mechanisms have been suggested (9) . NO is one of the molecule that takes a part in the pathophysiology of migraine. NO is involved in the regulation of the cerebral vessels tone. The design of the present study gave us an opportunity to compare the attack period plasma total nitrite levels of migraine cases, both with the attack-free period of the same group and with the control group. We found that plasma total nitrite levels elevated during migraine attacks and returned to low levels close to the control cases during the attack-free periods.
It is well known that migraine attacks may be provoked with the administration of NO donors. Infusion of NO donors may cause abrupt but nonspecific headaches. Apart from immediate headaches, more specific headaches, usually with associated features like nausea/vomiting and photophobia/phonophobia, following a few hours after the administration may also be initiated by NO donors (10, 11) . Migraine subjects are more susceptible to NO donors and they experience more severe headaches than healthy controls and tension type headache cases and the majority of migraineurs report that typical migraine without aura occurs within 3-6 hours following the administration (1,12) . Administration of high doses of NO donors may initiate migraine attacks even in healthy subjects (13) . It was also reported that administration of NOS inhibitor (L-NG methyl arginine hydrochloride) was successful in the treatment of headache and provided a decrease in accompanying symptoms such as photophobia and phonophobia (2) .
The mechanisms that are involved in delayed headaches have not yet been understood. Trigeminovascular system activation seems to be the key point for the initiation of migraine attacks. Therefore, NO may be involved in the initiation of a series of alterations, such as changes in the functions of ion channels, or calcitonin gene-related peptide (CGRP) or glutamate release that may result in migraine type headaches (14, 15) . CGRP is a significant molecule in this respect. Increased plasma CGRP level was reported previously in GTN-induced migraine attacks, supporting the concept that NO may be involved in basic mechanisms in migraine attacks. On the other hand, although CGRP antagonists may be helpful in migraine attacks, they do not relieve GTN-induced migraine attacks (16) . The most important effect of NO is the activation of the soluble guanylate cyclase. This enzyme causes the synthesis of cyclic guanosine monophosphate (cGMP) and NO-cGMP pathway in smooth vascular muscles causes vascular dilation and relaxation (10) . It is suggested that NO could be an important mediator in the initiation or the propagation of a neurogenic cranial vessel inflammatory response that might eventually result in a migraine attack (17) . Therefore NO may be involved in various mechanisms in migraine, some of which have not yet been discovered.
In the last twenty years, substantial information has been collected about the involvement of NO in the pathophysiology of migraine. However, current data cannot answer the question how endogenous NO alterations affect the natural course of migraine attacks. We do not even know which circumstances may induce the alterations of plasma NO levels in migraine cases; therefore, it is still not easy to translate previous data to clinical practice. Moreover, in contradiction to strong clues on involvement of NO in migraine attacks, new drug studies on inhibition of NO pathways have mostly failed to be an option for migraine treatment so far.
Our results supported that elevation of plasma NO levels might had an important role in migraine attacks. One of the limitations of the present study was the relatively small number of patients included in it. However, we believe that studying plasma nitrite levels in both attack-free and unprovoked attack periods in the same migraine group by comparing with controls is the strength of our study. We could not find a significant relationship between plasma nitrite levels of migraine cases and associated clinical or demographic features. So we could not make any comments on the patients' variables in relation to demographic or clinical data that might explain the involvement of NO pathways in the natural course of migraine. NO may be involved in some other primary headache types (18) (19) (20) , but probably not in the same manner as in migraine attacks (20) . On the other hand, it is not clear yet whether NO involvement in primary headaches is the cause or the consequence. Further studies regarding mediators involved in the modulation of pain in various headache states and even in clinically distant painful diseases would help to clarify the mechanisms of pain and would help expand our point of view.
